Phase IV Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis

Adelaide Hebert; Rhonda Schrieber; Debbie Glaab; Lawrence Eichenfield

doi:10.25251/skin.4.supp.77

Adelaide Hebert
Rhonda Schrieber
Debbie Glaab
Lawrence Eichenfield

Keywords

Psoriasis, Plaque Psoriasis, Topical Steroid, Halobetasol, Adrenal Suppression, Adolescent

Abstract

Abstract not available.

References

1. Bronker et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Pediatr Drugs (2015) 17:373-384

2. Paller et al. Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. J Drugs Dermatol. 2018;17(2):187-194.

3. Thomas et al. Treating pediatric plaque psoriasis: challenges and solutions. Pediatric Health, Medicine and Therapeutics 2016:7 25-38.

4. Bhatia et al. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects with Plaque Psoriasis. J Drug Dermatol. 2019 Aug 1;18(8):790-796

Poster PDF

Published

Oct 27, 2020

DOI https://doi.org/10.25251/skin.4.supp.77

How to Cite

Hebert, A., Schrieber, R., Glaab, D., & Eichenfield, L. (2020). Phase IV Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, 4(6), s77. https://doi.org/10.25251/skin.4.supp.77

Issue

Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)

Section

Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Amy Paller, Keith Knapp, Breda Munoz, Ami Claxton, Sanjeev Balu, Shannon Schnieder, Lawrence Eichenfield, Unmet Needs of Adolescents with Moderate to Severe Atopic Dermatitis in the TARGET DERM Registry , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Christopher Bunick, Neal Bhatia, James Del Rosso, Zoe Draelos, Lawrence Eichenfield, Leon Kircik, Mark Lebwohl, Melinda Gooderham, Lawrence Green, Adelaide Hebert, Ronald Vender, Matthew Zirwas, Eric Simpson, Linda Stein Gold, Melissa Seal, Scott Snyder, David Osborne, Patrick Burnett, Robert Higham, David Chu, David Berk, Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 1 (2024): January 2024 Issue
Michael Haft, Keith Knapp, Ami Claxton, Breda Munoz, Sanjeev Balu, Shannon Schnieder, Jonathan Silverberg, Diamant Thaci, Lawrence Eichenfield, Use of advanced systemic therapy in adolescent patients with moderate-to-severe atopic dermatitis in the TARGET-DERM Registry , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
James Del Rosso, H. Chih-ho Hong, Leon Kircik, Melinda Gooderham, Mark Lebwohl, Kim Papp, Linda Stein Gold, Adelaide Hebert, Melissa Seal, David Krupa, David Chu, Patrick Burnett, David Berk, Robert Higham, Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient PASI and PASI-HD Responses: Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 2 (2024): March 2024 Issue
James Del Rosso, H. Chih-ho Hong, Leon Kircik, Melinda Gooderham, Mark Lebwohl, Kim Papp, Linda Stein Gold, Adelaide Hebert, Melissa Seal, David Krupa, David Chu, Patrick Burnett, David Berk, Robert Higham, Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Individual Patient Response from the Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 1 (2024): January 2024 Issue
Adelaide Hebert, Debbie Glaab, Rhonda Schreiber, A Phase 1 Open -Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005% Applied Under Maximal Use Conditions in Adolescent Subjects with Plaque Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
James Del Rosso, Linda Stein Gold, Hilary Baldwin, Julie C. Harper, Leon Kircik, Richard G. Fried, Andrew F. Alexis, Evan A. Rieder, Adelaide Hebert, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Emmy Graber, Clinician Perception of Antibiotics and Antibiotic Resistance in the Context of Managing Acne Vulgaris (AV), and Satisfaction With AV Treatment Outcomes Among Patients Administered Sarecycline in Clinical Practices Across the US: Results from PROSES Study , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 1 (2024): January 2024 Issue
Adelaide Hebert, Julie C. Harper, Emmy Graber, Evan A. Rieder, Richard G. Fried, Linda Stein Gold, Andrew F. Alexis, Leon Kircik, James Del Rosso, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Hilary Baldwin, Patient and Caregiver Perception of Antibiotics and Antibiotic Resistance in the Context of Managing Acne Vulgaris (AV), and Patient Global Assessment (ptGA) of AV Among Patients Administered Sarecycline in US Clinical Practices: Results from PROSES Study , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 1 (2024): January 2024 Issue
Lawrence Eichenfield, Vivian Shi, JiaDe Yu, Evangeline Pierce, Amber Reck Atwater, Jenny Austin, Phoebe Salmon, James Piercy, Peter Anderson, Amy Paller, Understanding Flares in Pediatric and Adolescent Patients with Moderate or Severe Atopic Dermatitis: A Real-world Study in the United States and Europe , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Lawrence Eichenfield, Adelaide Hebert, Julie Harper, Hilary Baldwin, Neal Bhatia, Linda Stein Gold, Leon Kircik, Emmy Graber, Emil Tanghetti, Andrew Alexis, James Del Rosso, Efficacy and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne Vulgaris in Children and Adolescents , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 2 (2024): March 2024 Issue

<< < 1 2 3 4 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)